Livzon Pharmaceutical Group Inc. (SHE:000513)
31.06
-0.12 (-0.38%)
May 20, 2026, 11:15 AM CST
SHE:000513 Revenue
Livzon Pharmaceutical Group had revenue of 2.87B CNY in the quarter ending March 31, 2026, a decrease of -9.73%. This brings the company's revenue in the last twelve months to 11.71B, down -0.33% year-over-year. In the year 2025, Livzon Pharmaceutical Group had annual revenue of 12.02B with 1.76% growth.
Revenue (ttm)
11.71B
Revenue Growth
-0.33%
P/S Ratio
2.17
Revenue / Employee
1.32M
Employees
8,878
Market Cap
25.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.02B | 208.01M | 1.76% |
| Dec 31, 2024 | 11.81B | -617.70M | -4.97% |
| Dec 31, 2023 | 12.43B | -199.54M | -1.58% |
| Dec 31, 2022 | 12.63B | 565.72M | 4.69% |
| Jan 1, 2022 | 12.06B | 1.54B | 14.67% |
| Jan 1, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Humanwell Healthcare (Group) | 23.93B |
| Zhejiang Huahai Pharmaceutical | 8.55B |
| Tasly Pharmaceutical Group | 8.35B |
| Shijiazhuang Yiling Pharmaceutical | 7.91B |
| Hubei Jumpcan Pharmaceutical | 5.90B |
| Kangmei Pharmaceutical | 5.03B |
| Tianjin Pharmaceutical Da Ren Tang Group Corporation | 4.98B |
| Walvax Biotechnology | 2.40B |
Livzon Pharmaceutical Group News
- 26 days ago - Livzon Pharmaceutical Group Quarterly report: Q1 2026 - Filings
- 2 months ago - Livzon Pharmaceutical Group Annual report: Q4 2025 - Filings
- 7 months ago - Livzon Pharmaceutical Group Quarterly report: Q3 2025 - Filings
- 9 months ago - Livzon Pharmaceutical Group Quarterly report: Q2 2025 - Filings